本文選題：復(fù)方黃黛片 + 急性早幼粒細(xì)胞白血病�。� 參考：《中國(guó)新藥雜志》2017年10期

【摘要】：目的:評(píng)估復(fù)方黃黛片納入國(guó)家基本醫(yī)保目錄報(bào)銷對(duì)醫(yī)�；鹬С隹赡墚a(chǎn)生的影響。方法:基于國(guó)際藥物經(jīng)濟(jì)學(xué)與結(jié)果研究協(xié)會(huì)公布的預(yù)算影響分析指南,采用Excel構(gòu)建1個(gè)跨度5年的模型。模型中,急性早幼粒細(xì)胞性白血病(acute promyelocytic leukemia,APL)患者的發(fā)病率來(lái)源文獻(xiàn)分析;直接醫(yī)療成本等數(shù)據(jù)來(lái)源于從醫(yī)療機(jī)構(gòu)采集的費(fèi)用信息分析。復(fù)方黃黛片納入醫(yī)保報(bào)銷的替代比例來(lái)源于專家意見(jiàn)。結(jié)果:復(fù)方黃黛片納入國(guó)家醫(yī)保類報(bào)銷2018—2022年,砷劑費(fèi)用支出分別增加359.86,719.72,1 079.58,1 439.44和1 799.30萬(wàn)元;醫(yī)療總費(fèi)用分別少支出266.36,532.72,799.09,1 065.45和1 331.81萬(wàn)元;醫(yī)保基金分別節(jié)省135.92,271.84,407.76,543.68和679.60萬(wàn)元。以APL發(fā)病率的變化、復(fù)方黃黛片納入醫(yī)保目錄后替代注射砷劑比例和藥品價(jià)格變動(dòng)進(jìn)行敏感性分析,并不改變復(fù)方黃黛片進(jìn)入醫(yī)保目錄有利于節(jié)省醫(yī)保支出的結(jié)果。結(jié)論:復(fù)方黃黛片納入國(guó)家醫(yī)保報(bào)銷有利于優(yōu)化資源配置。
[Abstract]:Aim: to evaluate the possible impact of compound Huangdai tablets on Medicare fund expenditure. Methods: based on the guidelines for budget impact analysis published by the International Association for Pharmacoeconomics and results Research, a 5-year model was constructed with Excel. In the model, the incidence rate of patients with acute promyelocytic leukemia (promyelocytic) was analyzed by literature analysis, and the data of direct medical cost came from the analysis of cost information collected from medical institutions. The replacement ratio of compound Huangdai tablets into medical insurance reimbursement comes from expert opinion. Results: in the period of 2018-2022, the expense of arsenic agent increased by 359.86719.7210 79.582 yuan (1 439.44 yuan) and 17.993 million yuan (RMB) respectively, the total medical expenses were 266.36532.72% 799.09 yuan (1 065.45 yuan) and 13.3181 million yuan (RMB) respectively, and the medical insurance fund saved 135.9271.8407.763.68 yuan and 6.796 million yuan respectively. According to the change of incidence of APL, the sensitivity analysis of the ratio of arsenic injection and the change of drug price after the compound Huangdai tablet was included in the catalogue of medical insurance, it did not change the result that the compound Huangdai tablet entered the catalogue of medical insurance to save the medical insurance expenditure. Conclusion: compound Huangdai tablet is beneficial to optimize the allocation of resources.
【作者單位】： 北京醫(yī)藥衛(wèi)生經(jīng)濟(jì)研究會(huì);北京中醫(yī)藥大學(xué)管理學(xué)院;解放軍第306醫(yī)院;
【分類號(hào)】：R273

【相似文獻(xiàn)】

相關(guān)期刊論文 前4條

1 張晨 ,黃世林,向陽(yáng),郭愛(ài)霞;復(fù)方黃黛片誘導(dǎo)急性早幼粒細(xì)胞白血病細(xì)胞凋亡的研究[J];解放軍醫(yī)學(xué)雜志;2003年06期

2 魏艾紅;常曉慧;黃世林;;復(fù)方黃黛片治療慢性粒細(xì)胞白血病前后舌微循環(huán)觀察[J];世界科學(xué)技術(shù)-中醫(yī)藥現(xiàn)代化;2008年03期

3 成玉斌;向陽(yáng);常曉慧;陳楠楠;孫淑君;孫鋒;黃世林;;復(fù)方黃黛片對(duì)急性早幼粒細(xì)胞白血病患者心電圖QTC間期和ST-T的影響[J];臨床血液學(xué)雜志;2012年05期

4 ;[J];;年期

相關(guān)碩士學(xué)位論文 前2條

1 王修平;復(fù)方黃黛片應(yīng)用于急性早幼粒細(xì)胞白血病維持期治療中臨床對(duì)照觀察[D];廣州中醫(yī)藥大學(xué);2013年

2 焦志真;復(fù)方黃黛片在急性早幼粒細(xì)胞白血病鞏固強(qiáng)化治療中的臨床對(duì)照觀察[D];廣州中醫(yī)藥大學(xué);2012年

，

本文編號(hào)：1834938